Man Group PLC : Form 8.3 - FORM 8.3 PUBLIC

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
521
Man Group PLC : Form 8.3 - [GVC Holdings plc]

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Full name of discloser: Man Group Plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):                                                                      N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:                                                                      GVC Holdings plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
(e) Date position held/dealing undertaken:                                                                      14 th December 2017
(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?      YES / NO / N/A If YES, specify which: Ladbrokes Coral Group plc

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:   Euro 0.01 ordinary
    Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 674,384     0.2222   0 0
(2) Cash-settled derivatives:   6,586,746   2.1698   1,060,713       0.3494  
(3) Stock-settled derivatives (including options) and agreements to purchase/sell: 0 0 0 0
       TOTAL: 7,261,130     2.3920   1,060,713       0.3494  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)        Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale   Number of securities Price per unit
Euro 0.01 ordinary Purchase 349 9.1400
Euro 0.01 ordinary Purchase 12,020 9.1819
Euro 0.01 ordinary Purchase 19,504 9.2650

(b)        Cash-settled derivative transactions

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (GBP)
Euro 0.01 ordinary CFD Increasing a long position 1094 9.21840
Euro 0.01 ordinary CFD Reducing a short position 24 9.22750
Euro 0.01 ordinary CFD Increasing a long position 28488 9.21840
Euro 0.01 ordinary CFD Increasing a long position 85 9.21830
Euro 0.01 ordinary CFD Increasing a long position 70 9.21830
Euro 0.01 ordinary CFD Increasing a long position 1637 9.21830
Euro 0.01 ordinary CFD Increasing a long position 1496 9.21830
Euro 0.01 ordinary CFD Increasing a long position 56 9.21840
Euro 0.01 ordinary CFD Increasing a long position 1168 9.21840
Euro 0.01 ordinary CFD Increasing a long position 574 9.21830
Euro 0.01 ordinary CFD Increasing a long position 147 9.21830
Euro 0.01 ordinary CFD Increasing a long position 243 9.21840
Euro 0.01 ordinary CFD Opening a long position 17490 9.26500
Euro 0.01 ordinary CFD Increasing a long position 3736 9.18190
Euro 0.01 ordinary CFD Opening a long position 10777 9.18190
Euro 0.01 ordinary CFD Increasing a long position 6063 9.26500
Euro 0.01 ordinary CFD Increasing a long position 108 9.14000
Euro 0.01 ordinary CFD Opening a long position 313 9.14000
Euro 0.01 ordinary CFD Increasing a long position 20789 9.08500
Euro 0.01 ordinary CFD Increasing a long position 454 9.08610
Euro 0.01 ordinary CFD Increasing a long position 240 9.10970
Euro 0.01 ordinary CFD Increasing a long position 95 9.14000
Euro 0.01 ordinary CFD Increasing a long position 26390 9.21720
Euro 0.01 ordinary CFD Opening a long position 33750 9.07460
Euro 0.01 ordinary CFD Increasing a long position 212 9.10970
Euro 0.01 ordinary CFD Increasing a long position 18204 9.08500
Euro 0.01 ordinary CFD Increasing a long position 399 9.08610
Euro 0.01 ordinary CFD Increasing a long position 9178 9.09590
Euro 0.01 ordinary CFD Increasing a long position 5135 9.17650
Euro 0.01 ordinary CFD Increasing a long position 3272 9.18190
Euro 0.01 ordinary CFD Increasing a long position 5308 9.26500
Euro 0.01 ordinary CFD Increasing a long position 761 9.20390
Euro 0.01 ordinary CFD Increasing a long position 1073 9.20390
Euro 0.01 ordinary CFD Increasing a long position 4679 9.18190
Euro 0.01 ordinary CFD Increasing a long position 138 9.14000
Euro 0.01 ordinary CFD Increasing a long position 13083 9.09590
Euro 0.01 ordinary CFD Opening a long position 48219 9.07460
Euro 0.01 ordinary CFD Increasing a long position 7320 9.17650
Euro 0.01 ordinary CFD Increasing a long position 571 9.08610
Euro 0.01 ordinary CFD Increasing a long position 26036 9.08500
Euro 0.01 ordinary CFD Increasing a long position 37622 9.21720
Euro 0.01 ordinary CFD Increasing a long position 7590 9.26500
Euro 0.01 ordinary CFD Increasing a long position 302 9.10970
Euro 0.01 ordinary CFD Increasing a long position 68 9.08610
Euro 0.01 ordinary CFD Increasing a long position 16 9.14000
Euro 0.01 ordinary CFD Increasing a long position 4545 9.21720
Euro 0.01 ordinary CFD Opening a long position 5831 9.07460
Euro 0.01 ordinary CFD Increasing a long position 3141 9.08500
Euro 0.01 ordinary CFD Increasing a long position 36 9.10970
Euro 0.01 ordinary CFD Increasing a long position 1580 9.09590
Euro 0.01 ordinary CFD Increasing a long position 884 9.17650
Euro 0.01 ordinary CFD Increasing a long position 917 9.26500
Euro 0.01 ordinary CFD Increasing a long position 564 9.18190
Euro 0.01 ordinary CFD Increasing a long position 109 9.20390
Euro 0.01 ordinary CFD Increasing a long position 193 9.20390
Euro 0.01 ordinary CFD Increasing a long position 1358 9.26500
Euro 0.01 ordinary CFD Increasing a long position 24 9.14000
Euro 0.01 ordinary CFD Increasing a long position 837 9.18190
Euro 0.01 ordinary CFD Increasing a long position 1308 9.17650
Euro 0.01 ordinary CFD Increasing a long position 4656 9.08500
Euro 0.01 ordinary CFD Increasing a long position 2338 9.09590
Euro 0.01 ordinary CFD Increasing a long position 101 9.08610
Euro 0.01 ordinary CFD Opening a long position 8602 9.07460
Euro 0.01 ordinary CFD Increasing a long position 6726 9.21720
Euro 0.01 ordinary CFD Increasing a long position 53 9.10970
Euro 0.01 ordinary CFD Opening a long position 12376 9.26500
Euro 0.01 ordinary CFD Opening a long position 9731 9.18190
Euro 0.01 ordinary CFD Opening a long position 258 9.10970
Euro 0.01 ordinary CFD Opening a long position 2635 9.08500
Euro 0.01 ordinary CFD Increasing a long position 1889 9.21720
Euro 0.01 ordinary CFD Opening a long position 2444 9.07460
Euro 0.01 ordinary CFD Increasing a long position 45 9.10970
Euro 0.01 ordinary CFD Increasing a long position 15 9.10970
Euro 0.01 ordinary CFD Increasing a long position 86 9.08610
Euro 0.01 ordinary CFD Increasing a long position 28 9.08610
Euro 0.01 ordinary CFD Increasing a long position 656 9.09590
Euro 0.01 ordinary CFD Increasing a long position 3953 9.08500
Euro 0.01 ordinary CFD Increasing a long position 1316 9.08500
Euro 0.01 ordinary CFD Increasing a long position 367 9.17650
Euro 0.01 ordinary CFD Increasing a long position 236 9.18190
Euro 0.01 ordinary CFD Increasing a long position 710 9.18190
Euro 0.01 ordinary CFD Opening a long position 1898 9.18190
Euro 0.01 ordinary CFD Increasing a long position 384 9.26500
Euro 0.01 ordinary CFD Increasing a long position 1154 9.26500
Euro 0.01 ordinary CFD Opening a long position 3080 9.26500
Euro 0.01 ordinary CFD Increasing a long position 6 9.14000
Euro 0.01 ordinary CFD Increasing a long position 20 9.14000
Euro 0.01 ordinary CFD Opening a long position 55 9.14000
Euro 0.01 ordinary CFD Reducing a long position 123 9.21750
Euro 0.01 ordinary CFD Reducing a long position 2865 9.21750
Euro 0.01 ordinary CFD Reducing a long position 2266 9.16020
Euro 0.01 ordinary CFD Reducing a long position 1843 9.16600
Euro 0.01 ordinary CFD Increasing a long position 3 9.14000
Euro 0.01 ordinary CFD Increasing a long position 194 9.26500
Euro 0.01 ordinary CFD Increasing a long position 119 9.18190
Euro 0.01 ordinary CFD Increasing a long position 147 9.17650
Euro 0.01 ordinary CFD Increasing a long position 664 9.08500
Euro 0.01 ordinary CFD Increasing a long position 264 9.09590
Euro 0.01 ordinary CFD Increasing a long position 14 9.08610
Euro 0.01 ordinary CFD Increasing a long position 7 9.10970
Euro 0.01 ordinary CFD Increasing a long position 760 9.21720
Euro 0.01 ordinary CFD Opening a long position 1154 9.07460
Euro 0.01 ordinary CFD Reducing a long position 887 9.17920
Euro 0.01 ordinary CFD Reducing a long position 1486 9.17920
Euro 0.01 ordinary CFD Reducing a long position 323 9.21750
Euro 0.01 ordinary CFD Reducing a short position 4010 9.20130
Euro 0.01 ordinary CFD Reducing a short position 1960 9.20130
Euro 0.01 ordinary CFD Reducing a short position 1180 9.20130
Euro 0.01 ordinary CFD Reducing a short position 4220 9.20130
Euro 0.01 ordinary CFD Opening a long position 72385 9.26500
Euro 0.01 ordinary CFD Opening a long position 44607 9.18190
Euro 0.01 ordinary CFD Opening a long position 1295 9.14000
Euro 0.01 ordinary CFD Increasing a short position 11800 9.19790

(c)        Stock-settled derivative transactions (including options)

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii)        Exercise

Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit
           

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
       

4.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
  None  

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None  

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? YES/ NO
Date of disclosure: 15 th December 2017
Contact name: Matthew Irwin  
Telephone number: 02071447255

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading

Top 5 Most Recently Viewed Articles

SKK Holdings Limited Announces Pricing for Share IPO Offering

Updated Category News Views 65

SKK Holdings Limited Announces Share Pricing for IPO SKK Holdings Limited (“SKK” or the “Company”) (Nasdaq: SKK), a specialized civil engineering service provider in subsurface utility works, has proudly announced the pricing of its initial public offering. The Company will offer 2,500,000 ordinary shares at a public offering price of $4.00 per share, yielding...

Continue Reading
Antelope Enterprise: Financial Performance Insights for 2024

Updated Category News Views 149

Antelope Enterprise Holdings Limited (NASDAQ: AEHL) hit the financial report stage hard back in mid-2024, flaunting numbers that tell quite the tale of both triumphs and tribulations. This company was hustling across two growing fronts: the fast-paced world of livestreaming ecommerce and the burgeoning energy sector down in Texas. Their half-year performance review...

Continue Reading
Olivier Falut Steps Into CFO Role at EUROAPI to Drive Growth

Updated Category News Views 344

Olivier Falut Joins EUROAPI as the New Chief Financial Officer EUROAPI is excited to announce the appointment of Olivier Falut as its new Chief Financial Officer, effective immediately. Olivier will be an integral member of the Executive Committee, succeeding Evelyne Nguyen. Evelyne will ensure continuity and a smooth transition within the company through her support...

Continue Reading
OPEXUS and Casepoint Join Forces for Growth and Innovation

Updated Category News Views 261

OPEXUS and Casepoint Unite for Strategic Growth In a significant development in the technology sector, OPEXUS, a frontrunner in government process management software, and Casepoint, an innovator in data discovery technology, have announced their merger. This significant move comes along with a majority investment from Thoma Bravo, a renowned software investment firm...

Continue Reading
MeiraGTx Holdings: An In-Depth Look at Future Potential

Updated Category News Views 69

MeiraGTx Holdings plc (NASDAQ:MGTX) was a clinical-stage gene therapy firm making waves back in 2024. The company announced a pivotal financial move, securing $50 million through equity financing at $4 per share, largely thanks to a $30 million investment from Sanofi (NYSE:SNY). While this funding boosted MGTX’s war chest, traders were already whispering about the heavy...

Continue Reading